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Influenza is a public health priority in Europe. The impact of 
influenza pandemics on public health is very high, but sea-
sonal influenza also constitutes an important burden in terms 
of hospitalisation and excess deaths. Influenza vaccination 
is a fundamental pillar of disease prevention. In the absence 
of a clear decision-making process for vaccination policies, 
EU institutions have, in recent years, fostered collaboration 
among Member States. Such collaboration was closer during 
the 2009 pandemic, which constituted a clear cross-border 
threat to EU citizens’ health. The EU institutions have been 
supporting national vaccination programmes by providing 
evidence of the effectiveness and safety of influenza vaccina-
tion. Decision 1082/2013 was a major step toward EU collab-
oration, in that it highlighted the role of pandemic vaccination 
in the field of preparedness and emergency response, in which 
concerted action is clearly valuable.
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Summary
Introduction
Influenza prevention is a public health priority world-
wide. In Europe, seasonal influenza causes between 4 
and 50  million symptomatic cases each year and the 
death toll associated with influenza is estimated at be-
tween 15,000 and 70,000 every influenza season, in 
terms of excess deaths  [1]. The impact of influenza is 
even greater in the case of pandemics, when large popu-
lation age-groups – if not the entire population – are im-
munologically naïve toward the pandemic viral strain. 
During the 2009 H1N1 pandemic, 2,900 deaths directly 
related to influenza were reported by the European Un-
ion (EU) Member States during the first 12 months [2], 
but the increase in mortality rates related to the pan-
demic virus is estimated to be larger. In addition, the 
high number of cases occurring in a short period of time 
places a heavy load on the healthcare system during the 
influenza season.
Preventive measures to limit the spread of influenza in-
clude both individual and public health interventions. 
Frequent hand-washing and correct respiratory hygiene 
have proved to be effective in preventing respiratory 
illnesses, including influenza  [3, 4]. However, influen-
za vaccination is still the main tool for preventing the 
spread of influenza spread and limiting the burden on 
public health. In the US, routine annual influenza vacci-
nation is recommended for all persons aged ≥ 6 months 
who do not have contraindications  [5]. Recommenda-
tions are more limited in the EU, and vary widely among 
Member States [6].
This paper presents an overview of the European ap-
proach to influenza prevention and describes the point 
of view of European decision-makers regarding both 
seasonal and pandemic prevention policies.
The EU decision-making process  
with regard to vaccination policies 
In the EU, responsibility for immunisation programmes, 
including immunisation schedules, their mandatory or 
voluntary character and their financing, lies with the in-
dividual Member States. As clearly stated in art. 168 of 
the Lisbon Treaty, harmonisation of national laws and 
regulations in the field of human health promotion is ex-
cluded. On the other hand, the same article reads “The 
Union shall encourage cooperation between the Member 
States […] and, if necessary, lend support to their action. 
It shall in particular encourage cooperation between the 
Member States to improve the complementarity of their 
health services in cross-border areas” [7]. Definitively, 
even though decisions on vaccination issues are taken 
essentially at the national level, there may nevertheless 
be some room for action at the European level in terms 
of support and cooperation between national and EU 
decision-makers.
During the last few years, for the first time since the 
foundation of the EU, some pieces of legislation have 
been delivered by EU institutions in the specific area 
of vaccination programmes. Specifically, in 2011 and 
2014, two Council Conclusions were delivered during 
the Employment, Social Policy, Health and Consumer 
Affairs Council meeting under, the Hungarian and Ital-
ian Presidencies, respectively. These two Council Con-
clusions both move in the direction of fostering the ef-
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forts of EU Member States to strengthen vaccination 
programmes, thus underlining the great importance and 
societal value of immunisation [8, 9]. More importantly, 
in December 2009, a few months after the declaration 
of the H1N1 pandemic, a recommendation on seasonal 
influenza vaccination was issued by the Council of the 
EU  [10]. In this recommendation, EU Member States 
“are encouraged to adopt and implement […] action 
plans or policies […] aimed at improving seasonal influ-
enza vaccination coverage, with the aim of reaching, as 
early as possible and preferably by the 2014-2015 winter 
season, a vaccination coverage rate of 75% for ‘older 
age-groups’ and, if possible, for other risk groups […]. 
Member States are also encouraged to improve vacci-
nation coverage among healthcare workers”. Moreover, 
Member States should draw up specific action plans 
aimed at monitoring influenza vaccine coverage and in-
vestigating the reasons for low adherence to vaccination. 
Even though Council recommendations are not binding 
on the Member States, this recommendation on influ-
enza vaccination is nevertheless the first of its kind in 
the field of vaccines, and demonstrates the great interest 
of European decision-makers in influenza prevention. 
Indeed, the seasonal influenza coverage rates reported 
by EU Member States are widely variable and mostly 
suboptimal. There is no statutory system for collecting 
and monitoring adherence to influenza vaccination in 
the EU. For this reason, a network of experts (VENICE 
consortium, Vaccine European New Integrated Collabo-
ration Effort) [11] supported by a grant from the Euro-
pean Centre for Disease Prevention and Control (ECDC) 
started a regular survey in 2006 to collect, among other 
data, information on influenza vaccine coverage. The re-
sults of the VENICE influenza surveys are publicly avail-
able at the VENICE website [11]. Two major issues arise 
from the analysis of vaccine coverage data. Firstly, only 
in the Netherlands and some parts of the United King-
dom is the target of 75% of vaccination coverage among 
elderly people reached. Moreover, data are available 
from 23 Member States only, and not from all influenza 
seasons. On the other hand, comparison of the available 
data on vaccination coverage in the general population 
in 2008-2009 (seasonal) and in 2009-2010 (pandemic), 
reveals some evidence that, during a pandemic, vaccina-
tion levels are very similar to those reached during a nor-
mal influenza season. It would appear that the same peo-
ple who receive seasonal influenza vaccines are reached 
during pandemic vaccination programmes. Therefore, 
pandemic influenza vaccination is better implemented 
where a well-functioning seasonal influenza vaccination 
programme is already in place. This evidence supports 
the need to strengthen seasonal influenza vaccination 
programmes as part of preparedness plans for future 
pandemics. Pandemic influenza preparedness plans are 
a clear area of intervention for EU institutions, since an 
influenza pandemic is a typical cross-border threat [7]. 
Therefore, in addition to the clear benefits yielded by a 
strong seasonal influenza vaccination programme, this 
is a good reason for the EU to support Member States in 
improving their programmes.
How EU can support national influenza 
programmes
The EU decision-maker has limited power to influence 
national vaccination policies. On the other hand, influ-
enza prevention is perceived as a priority at the EU level 
because of the potential pandemic threat and its subse-
quent cross-border issues. As a consequence, the role 
of the EU – also fostered by the 2009 Council Recom-
mendation –  has been to support national vaccination 
programmes by providing evidence of the effectiveness 
and safety of influenza vaccination. The perceived low 
effectiveness of influenza vaccines and the fear of al-
leged adverse events are considered the main obstacles 
to improving vaccination adherence. Providing national 
vaccination programme managers with reliable data on 
post-marketing evaluation of influenza vaccines may 
constitute an evident added value. To this end, the ECDC 
has funded the I-MOVE project  [12]. Since the 2008-
9 influenza season, I-MOVE has provided estimates of 
vaccine effectiveness that are usually available a few 
months after the end of the season. Thanks to a stand-
ardised protocol and a fairly large number of participat-
ing study sites, these estimates have good geographical 
representativeness [13]. In addition, only as a result of 
European collaboration can the study population reach a 
size large enough to yield robust estimates.
As expected, influenza vaccine effectiveness is strongly 
dependent on the quality of matching between vaccine 
strains and circulating virus strains. This was particu-
larly evident during the 2009 pandemic, when the only 
circulating strain was the pandemic one and vaccine ef-
fectiveness was particularly high, reaching 78.4% (95% 
CI 54.4-89.8) in patients aged < 65 years [14]. Defini-
tively, vaccine effectiveness estimates obtained from 
such collaborative studies can provide good-quality 
evidence to support communication. A real perception 
of the effectiveness of influenza vaccines is a prereq-
uisite to communicating the real benefits of influenza 
vaccination to the public. Indeed, suboptimal effective-
ness – during some seasons it may be even lower than 
50% –  may be negatively perceived at the individual 
level, even though the impact of the vaccination pro-
gramme on public health may be considerable in terms 
of the lowered global burden of disease.
Vaccine safety issues are another potential obstacle to 
influenza vaccine acceptance. Indeed, vaccines, unlike 
other drugs and medical interventions, are administered 
both to healthy subjects and to fragile individuals, such 
as very young children and elderly people. For this rea-
son, any potential safety issue is usually overestimated 
and the fear of alleged adverse events following immu-
nisation (AEFI) is the main reason why many people are 
sceptical towards vaccination. Vaccine safety monitor-
ing is strictly regulated in the EU, with the European 
Medicine Agency (EMA) playing a crucial role, espe-
cially during the pre-marketing phase [15]. On the other 
hand, monitoring and assessing vaccine safety during 
the post-marketing phase may present some challenges 
in the absence of a clear commitment. Responsibility for 
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post-marketing surveillance is shared between pharma-
covigilance authorities and vaccine producers. The basic 
system of AEFI surveillance is constituted by the statu-
tory pharmacovigilance system – shared with all other 
drugs – present in all EU Member States and coordinat-
ed by the EMA through the Eudravigilance system [16]. 
This is a routine passive surveillance system, which is 
good enough to detect clear safety signals, but not suf-
ficiently well designed to support vaccine programme 
managers who deal with vaccine hesitancy or anti-vac-
cine lobbies. For this purpose, pre-emptive strategies are 
needed, and good evidence on alleged adverse events 
should be rapidly available to vaccine managers. 
Post-marketing studies to assess vaccine safety are 
complex and expensive. EU-wide collaboration in this 
field is a clear added value, as recently demonstrated af-
ter the marketing of A(H1N1) pandemic vaccines. The 
VAESCO consortium (Vaccine adverse events surveil-
lance and communication) –  a consortium of public 
health institutions sponsored by the ECDC  [17] with 
the purpose of starting a European collaboration in the 
field of post-marketing vaccine surveillance – assessed 
the risk of Guillain-Barré syndrome (GBS) by means 
of a multinational case-control study  [18] followed by 
a prospective self-controlled case series study [19]. The 
conclusion of both studies was that the risk of GBS was 
not significantly elevated after influenza A(H1N1) pan-
demic vaccination; this research was made possible only 
by EU collaboration, which ensured a population size 
large enough to achieve the necessary study power [19].
Finally, the valuable role of the EU was clearly shown 
when an unexpected increase in narcolepsy cases was re-
ported in Finland and Sweden in 2010, after vaccination 
with Pandemrix® [20]. In that case, too, the EU commit-
ted a substantial amount of resources to assessing the nar-
colepsy signal. The VAESCO consortium conducted an 
ECDC-sponsored study in six EU Member States, which 
provided evidence of the association between narcolepsy 
cases in adolescents and Pandemrix® vaccination [21].
Vaccination as a preparedness measure 
against cross-border threats
Although the EU institutions cannot make any attempt 
to harmonise human vaccination practices, they should 
foster cooperation between Member States with regard 
to cross-border health threats. The level of cooperation 
and the limits of EU coordination in this field were re-
cently defined by the Decision of the European Parlia-
ment and of the Council N° 1082/2013/EU on serious 
cross-border threats to health [22]. The Decision, which 
is binding and is to be implemented at the national level, 
provides the EU Member States with four benefits: 1) 
preparedness planning capacity should be reinforced, to 
ensure that all Member States are adequately prepared in 
the event of an emerging crisis; 2) risk assessment and 
management should be improved at the national level, 
with the support of the EU agencies responsible (ECDC, 
EMA etc.); 3) a new mechanism for the joint procure-
ment of vaccines and medicines in the event of a health 
emergency is in place, in order to ensure the provision 
of emergency vaccine/medications in all Member States; 
4) the response at the EU level will be coordinated by 
the Health Security Committee, which has a solid le-
gal mandate to quickly take decisions in the event of an 
emergency.
Decision 1082 constitutes a major step toward EU col-
laboration in the field of infectious disease prevention. 
In particular, two main principles regarding vaccination 
are evident: a) vaccines are an important component of 
emergency preparedness; b) a mechanism for purchas-
ing vaccines through EU joint procurement is in place, 
which also provides a clear advantage deriving from the 
economy of scale. In particular, seasonal influenza vac-
cination should be an important component of pandemic 
preparedness, since a strong vaccination system for sea-
sonal influenza is clearly necessary in order to achieve 
good coverage during a pandemic. In addition, the joint 
procurement mechanism has been specifically set up 
to support the weaker Member States, which may have 
difficulty purchasing pandemic vaccines. This demon-
strates that the EU decision-maker does acknowledge 
the strategic role of influenza vaccination in preparing 
Europe to tackle the pandemic threat.
Conclusions
EU decision-making in the field of influenza prevention, 
as well as of all other vaccination policies, is not clearly 
established. Nevertheless, there is quite large room for 
collaboration, especially in the field of post-marketing 
vaccine surveillance. In addition, there is a clear added 
value in the area of emergency preparedness and re-
sponse, in which common EU policies, and even the 
joint procurement of vaccines, are ensured in the event 
of a pandemic.
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